An Antiangiogenic Peptide Fragment of beta-Amyloid Suppresses Glioma Proliferation, Angiogenesis, Invasiveness in a Syngeneic, Orthotopic Mouse Model.

Murphy SF, Banasiak M, Yee G-T, Obadia M, Tran Y, Prak A, Albright R, Mullan M, Paris D, Brem S

INTRODUCTION

The recent clinical success of bevacizumab to suppress angiogenesis, prolong of progression-free survival, and decreases tumor volume is proof of principle that inhibitors of angiogenesis are an effective approach for the treatment of human glioblastoma. Glioma invasion, however, remains a serious, unanswered clinical problem. An important source of drug discovery in glioblastoma anti-angiogenesis and anti-invasion research are naturally occurring inhibitors that play a role in health and disease within the central nervous system. We previously reported that the full length Aβ1-40 amyloid protein is a dose-dependent inhibitor of angiogenesis that also suppresses human U87 glioblastoma subcutaneous xenografts in nude mice (Paris D et al., Angiogenesis, 2004). We subsequently characterized a small peptide sequence of the Abeta amyloid, VH-GKLVFF, as a potent and novel anti-angiogenic molecule (Patel NS et al, Amyloid, 2008). In order to translate these findings to the clinic, we evaluated the effect of this peptide on a syngeneic, orthotopic model characterized by rapid, invasive growth.

AIM

The aim of this study was to determine effectiveness of Aβ in the treatment of malignant glioma.

METHODS

C57/Bl6 immunocompetent mice were implanted with 1 x 105 cells in 2ul GL261 syngeneic murine primary glioma. The animals were randomized to two groups, received intraperitoneal injection of either the active Aβ11-20, 50 mg/kg/day (n=10) or control (n=12) comprised of inactive vehicle. The treatment started on day 9 after tumor implantation and continued until day 27 when the brains were harvested and stained with H&E (invasion), Ki-67 (proliferation) and CD31 (microvascular density).

RESULTS

➢ The gliomas in the treated animals were much smaller with a decreased microvascular density (angiogenesis).
➢ There was an inhibition of glioma invasiveness in the treated mice.
➢ The proliferation rate was reduced in the gliomas in the treated group, P < 0.02.
➢ Toxicity related to the drug was not observed.

CONCLUSIONS

These results indicate that systemic delivery of a potent, antiangiogenic motif of the Aβ amyloid protein leads to a reduction in glioma proliferation, angiogenesis, and invasiveness. Furthermore, parallel experiments in a genetically-engineered model with animals that overexpress the amyloid precursor protein (APP) also showed reduction of glioma growth and angiogenesis (Paris D, Mullan M, Banasiak M, Yee G-T, Murphy, S., Brem S, unpublished data). Taken together, these findings warrant further studies to determine the pharmacokinetics and toxicology in preclinical models to warrant consideration for phase I clinical trials for patients with glioblastoma.

ACKNOWLEDGEMENTS

Supported by NIH/NIA grant RO1-AGO19250-08, The Greg Waterle Foundation of the FBTA, and the Moffitt Foundation.